Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Christchurch, Canterbury, New Zealand Clinical Trials

A listing of Christchurch, Canterbury, New Zealand clinical trials actively recruiting patients volunteers.

RESULTS

Found (11) clinical trials

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

This is a Phase 2, uncontrolled, three-stage, dose-escalation cohort study in subjects with three forms of TMA: atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenia (TTP), and hematopoietic stem cell transplant -associated TMA (HSCT-associated TMA). In the first stage, OMS721 will be administered to escalating dose cohorts of three subjects per ...

Phase

0.0 miles

Learn More »

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This is a multicenter, open-label Phase 2b study of the SINE compound, selinexor. A fixed 60mg dose of selinexor is given orally to patients with relapsed/refractory DLBCL who have no therapeutic options of demonstrated clinical benefit. One hundred thirty patients with relapsed/refractory DLBCL who meet eligibility criteria and have none ...

Phase

0.0 miles

Learn More »

Improving the Treatment for Women With Early Stage Cancer of the Uterus

Currently the standard treatment for early stage endometrial cancer or endometrial hyperplasia with atypia is a total hysterectomy (an operation to remove the uterus) and removal of both ovaries. While highly effective, this surgery carries significant side effects for: young women who still wish to have children and would lose ...

Phase

0.0 miles

Learn More »

Safety Tolerability and Efficacy of Etrasimod (APD334) in Patients With Primary Biliary Cholangitis

The purpose of this open-label, pilot, proof of concept study is to evaluate the safety, tolerability, and efficacy of oral etrasimod (APD334) in patients with primary biliary cholangitis (PBC).

Phase

0.0 miles

Learn More »

KISS Study: Kinase Inhibition With Sprycel Start up

The KISS Study is a Phase II, multicentre, open-label, prospective non-randomised study of treatment modification in response to maintenance of MR3.0 at 12 months. Patients must be newly diagnosed with chronic phase CML (CML-CP) (<3 months) and previously untreated with the exception of hydroxyurea. Patients will be recruited from hospital ...

Phase

0.0 miles

Learn More »

Study of Tumour Focused Radiotherapy for Bladder Cancer

RAIDER has a two stage design. Stage 1 will establish the feasibility of delivering DART in a multi-centre setting, and stage 2 will establish the toxicity of DART. 72 patients will be recruited in stage 1, with an additional 168 patients in stage 2. Both fractionation regimens in standard use ...

Phase

0.0 miles

Learn More »

Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)

The study will be a multicentre, prospective, randomized, open- label, blinded endpoint (PROBE), controlled phase 2 trial (2 arm with 1:1 randomization) in ischemic stroke patients. Randomized patients will first be stratified by both the setting of treatment: metropolitan hospital vs regional hospital (>1 hour transfer to endovascular centre) vs ...

Phase

0.2 miles

Learn More »

A Study Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17b Deletion

This is a Phase 2, open-label, single-arm, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) in the presence of 17p deletion.

Phase

0.2 miles

Learn More »

A Phase IIa Study With Escalating Dose of MS1819-SD

This is a Phase IIa study sponsored by AzurRx SAS and Syneos Health is a local representative sponsor and involves testing of a new medication for the compensation of exocrine pancreatic insufficiency (EPI) caused by chronic pacreatitis (CP) and/or distal pancreatectomy. The new medication is called MS1819 Spray Dried (MS1819-SD) ...

Phase

0.2 miles

Learn More »

Safety Tolerability Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Phase

1.67 miles

Learn More »